[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@OncBrothers Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1424530007574122497.png) @OncBrothers Oncology Brothers

Oncology Brothers posts on X about matterhorn, os, mos, hl the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1424530007574122497/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424530007574122497/c:line/m:interactions.svg)

- X Week XXXXXX +5%
- X Month XXXXXX -XX%
- X Months XXXXXXX +1.10%
- X Year XXXXXXX +70%

### Mentions: X [#](/creator/twitter::1424530007574122497/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424530007574122497/c:line/m:posts_active.svg)

- X Week XX -XXXX%
- X Month XX -XX%
- X Months XX +83%
- X Year XXX +130%

### Followers: XXXXXX [#](/creator/twitter::1424530007574122497/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424530007574122497/c:line/m:followers.svg)

- X Week XXXXXX +0.60%
- X Month XXXXXX +1.70%
- X Months XXXXXX +11%
- X Year XXXXXX +31%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1424530007574122497/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1424530007574122497/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[travel destinations](/list/travel-destinations) 

**Social topic influence**
[matterhorn](/topic/matterhorn) #57, [os](/topic/os) #902, [mos](/topic/mos), [hl](/topic/hl), [gain](/topic/gain), [sharma](/topic/sharma), [the first](/topic/the-first), [heme](/topic/heme)

**Top accounts mentioned or mentioned by**
[@oncoalert](/creator/undefined) [@usfda](/creator/undefined) [@oncupdates](/creator/undefined) [@asco](/creator/undefined) [@myesmo](/creator/undefined) [@bijoytelivala](/creator/undefined) [@drsgraff](/creator/undefined) [@fdaoncology](/creator/undefined) [@erikahamilton9](/creator/undefined) [@targetedonc](/creator/undefined) [@yjanjigianmd](/creator/undefined) [@gicancerdoc](/creator/undefined) [@narjustflorezmd](/creator/undefined) [@cathyengmd](/creator/undefined) [@dryakupergun](/creator/undefined) [@marklewismd](/creator/undefined) [@vkaklamani](/creator/undefined) [@rutikamehtamd](/creator/undefined) [@rachnatshroff](/creator/undefined) [@ashhematology](/creator/undefined)
### Top Social Posts
Top posts by engagements in the last XX hours

"Durvalumab + FLOT✂Durva now @FDAOncology ✅ for resectable GEJ/Gastric Ca based off #MATTERHORN study. - Improved OS in all comers (HR: 0.78) - Rate of✂ # of FLOT and AEs (Gr X & 4: 71%) similar in both arms. #OncTwitter @OncoAlert @OncUpdates @YJanjigianMD 👏👏"  
[X Link](https://x.com/OncBrothers/status/1993395526600212886)  2025-11-25T19:05Z 19.8K followers, 17.8K engagements


"Durvalumab (+FLOT) is now @US_FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN We 🗣 this trial findings PDL1 and AEs w/ @YJanjigianMD Full 🗣:  Also on Oncology Brothers podcast @OncoAlert @OncUpdates #gism"  
[X Link](https://x.com/OncBrothers/status/1993705708794319248)  2025-11-26T15:37Z 19.8K followers, 9624 engagements


"One page takeaway/summary from our 🗣 with @YJanjigianMD and #MATTERHORN study that resulted in #Durvalumab @FDAOncology approval on November XX 2025 for resectable GEJ/Gastric adenocarcinoma #OncTwitter #gism #MedTwitter @OncUpdates"  
[X Link](https://x.com/OncBrothers/status/1994050911195259241)  2025-11-27T14:29Z 19.8K followers, 8350 engagements


"Highlights from #ASH25 #CommunityOnc: #Lymphoma X. #EPCOREFL1 FL X. #CLL17 CLL X. #BRUIN313/314 CLL X. #S1826 HL #Myeloma X. #COBRA X. #MajesTEC3 X. #AQUILA X. #RedirecTT1 #Leukemia X. #PARADIGM @ASH_hematology #lymsm #mmsm #HemeTwitter 1/10"  
[X Link](https://x.com/OncBrothers/status/1998444129613734363)  2025-12-09T17:26Z 19.8K followers, 10.6K engagements


"2. Pooled NeoAdj Carboplatin analysis in TNBC from BrighTNess CALGB 40603 GeparSixto: - Carbo in NeoAdj improved pCR (OR 1.89) EFS (HR 0.71) but not OS - In gBRCA EFS was even better (HR 0.50) but no pCR/OS gain. 3/5"  
[X Link](https://x.com/OncBrothers/status/1998565526059258185)  2025-12-10T01:28Z 19.8K followers, XXX engagements


"3. #RJBC1501: PhIII Adjuvant Carbo to ECtaxane - 5yr DFS XXXX% vs XXXX% (HR 0.66) - OS HR XXXX - Gr 3/4 heme toxicity 4/5"  
[X Link](https://x.com/OncBrothers/status/1998565535047377294)  2025-12-10T01:28Z 19.8K followers, 1502 engagements